Treatments and diagnostics for cancers
AssigneeWayne State University
InventorsQingping Dou, Huanjie Yang, Elisabeth I. Heath
Life of this patent
Estimating the term…
Abstract
Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).
Claims17
A method of providing an anti-cancer effect in a subject having a solid tumor cancer or a liquid cancer, comprising administering a therapeutically effective amount of Galeterone and a therapeutically effective amount of a proteasome inhibitor to the subject, thereby providing an anti-cancer effect in the subject.
A method to target one or more deubiquitinating enzymes (DUBs), comprising administering a therapeutically effective amount of Galeterone in vivo or in vitro, thereby targeting DUBs.
Dependencies are inferred from the claim text.